Screener
Aclaris Therapeutics ACRS Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Licensing | 1,273 | 1,335 | 2,732 | 2,345 |
| Total revenue | 1,629 | 1,777 | 3,625 | 3,232 |
| Costs and expenses: | ||||
| Cost of revenue | 218 | 515 | 613 | 1,021 |
| Research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's total cost of revenue?
- Aclaris Therapeutics (ACRS) reported total cost of revenue of $218K in Q2 2026.
- How has Aclaris Therapeutics's total cost of revenue changed year-over-year?
- Aclaris Therapeutics's total cost of revenue decreased by 57.7% year-over-year, from $515K to $218K.
- What is the long-term trend for Aclaris Therapeutics's total cost of revenue?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's total cost of revenue has grown at a -18.4% compound annual growth rate (CAGR), from $4.71M to $2.09M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Aclaris Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude